**Benefits** 

aggregates

**Reduced costs** 

loadings

volume

**Increased performance** 

Superior flow-through removal of mAb

• High product recoveries at high mass

• Significant reduction in resin and buffer

Smaller manufacturing footprint (smaller

columns, buffer tanks, etc.)

# Data Sheet

# Eshmuno<sup>®</sup> CP-FT Resin

A cation exchange resin specifically developed for the flow-through removal of aggregates using frontal chromatography

Aggregates in monoclonal antibody (mAb) therapeutics pose a significant risk to patients by increasing the potential of an immunogenic response and reducing efficacy. In contrast to other mAb impurities, aggregates are not efficiently removed by protein A chromatography. They are particularly challenging to separate from the monomeric protein since they have very similar isoelectric points and hydrophobicities.

Eshmuno<sup>®</sup> CP-FT cation exchange (CEX) resin is specifically designed to provide efficient removal of mAb aggregates in the flow-through frontal chromatography mode of operation enabling loading capacities 10× higher than traditional bind/elute CEX chromatography. Eshmuno<sup>®</sup> CP-FT resin facilitates greater manufacturing flexibility and process intensification while reducing the overall cost for the downstream purification of mAbs.

# Intensified process

- Low salt process conditions eliminate the need for dilution before subsequent ion exchange steps
- Significant reduction in processing volumes improves virus filtration and ultrafiltration processing economics

# Enhanced ease of use

• Rigid base bead enables higher flow rates and easier column packing










# **Enabling Flow-Through Efficiency**


Eshmuno<sup>®</sup> CP-FT resin was developed for the efficient flow-through removal of aggregates under strong binding conditions (pH 4.0-5.5, 3-7 mS/cm) that favor frontal chromatography. Under these conditions, both the mAb monomer product and the mAb aggregates will initially bind to the Eshmuno<sup>®</sup> CP-FT resin. The resin has a novel CEX tentacle surface chemistry (Figure 1) that facilitates displacement of the bound monomer by the larger aggregates enabling efficient removal of aggregates using a frontal chromatography mechanism.

The example in Figure 2 demonstrates the efficient removal of aggregates from mAb feed containing a challenging level of aggregates (7%). The monomer breaks through the column much earlier than the aggregates. Thus, the monomer recovery exceeds 85% at 600 g/L while the percentage of aggregates in the flow-through pool does not reach 1% until after a loading of 1000 g/L.



#### Figure 1.


Resin tentacles form a multipoint three-dimensional ion exchange network that enables easy access of the proteins to the ligands providing fast mass transport.



#### Figure 2.

Cumulative recovery of mAb05 monomer as a function of the mass of mAb05 loaded onto the column (blue—). Cumulative percentage of aggregates as a function of the mass of mAb05 loaded onto the column (pink—).

Using Eshmuno<sup>®</sup> CP-FT resin for high loading flow-through CEX chromatography offers significant savings over conventional CEX bind/elute chromatography processes. For instance, purifying 1 kg of a mAb using Eshmuno<sup>®</sup> CP-FT resin at a loading of 1,000 g/L would only require 1 L of resin and 15 L of buffer (Figure 3). This is significantly less than a CEX bind/elute chromatography process loaded to 80 g/L that would require 12.5 L of resin and 313 L of buffer.




### Figure 3.

Volume of columns to purify 1 kg of mAb.

# **Demonstrated Performance**

The removal of aggregates and HCP was examined as part of a three-step downstream purification for two different mAb feed streams (Figure 4). The three-step purification was composed of a protein A affinity chromatography step (Eshmuno<sup>®</sup> A resin), a CEX chromatography step in the bind/elute mode (Eshmuno<sup>®</sup> CPX resin) or in the flow-through mode (Eshmuno<sup>®</sup> CP-FT resin), followed by a strong anion exchange (AEX) resin (Eshmuno<sup>®</sup> Q resin).



#### Figure 4.

Flow chart of the 3-step purification of mAb05 and mAb02. The loadings used for each purification step are listed below the respective unit operation.

## Table 1.

Comparison of a 3-step process having a CEX bind/elute chromatography step to a 3-step process having a CEX flow-through frontal chromatography step for the purification of mAb05.

Chromatography Step	Loading (g/L)	Monomer recovery	Aggregates in pool	HCP in pool (ppm)	mAb concentration (g/L)
1. Capture: Eshmuno <sup>®</sup> A resin (adjusted to pH 5.0)	40	88%	3.06%	47	15.1
2. CEX bind/elute: Eshmuno® CPX resin	80	87%	0.42%	3	15.8
3. AEX flow-through: Eshmuno® Q resin	150	>99%	0.43%	1	3.1
2. CEX flow-through: Eshmuno® CP-FT resin	1,000	92%	0.55%	17	13.6
3. AEX flow-through: Eshmuno® Q resin	150	>99%	0.61%	3	8.7

#### Table 2.

Comparison of a 3-step process having a CEX bind/elute chromatography step to a 3-step process having a CEX flow-through frontal chromatography step for the purification of mAb02.


Chromatography Step	Loading (g/L)	Monomer recovery	Aggregates in pool	HCP in pool (ppm)	mAb concentration (g/L)
1. Capture: Eshmuno <sup>®</sup> A resin (adjusted to pH 6.0)	35	97%	2.88%	228	14.9
2. CEX bind/elute: Eshmuno® CPX resin	60	98%	1.84%	63	9.9
3. AEX flow-through: Eshmuno® Q resin	150	>99%	1.44%	4	3.1
1. Capture: Eshmuno <sup>®</sup> A resin (adjusted to pH 4.0)	35	97%	2.43%	302	15.4
2. CEX flow-through: Eshmuno® CP-FT resin	1,000	91%	0.77%	181	13.7
3. AEX flow-through: Eshmuno <sup>®</sup> Q resin	150	>99%	0.98%	9	8.5

Case study #1 with mAb05 demonstrated that the 3-step process with a CEX flow-through frontal chromatography step loaded to 1,000 g/L removed similar amounts of HCP and aggregates to the 3-step process with a bind/elute CEX chromatography step loaded to 80 g/L. The CEX flow-through step results in a lower conductivity feed eliminating the need for dilution prior to the AEX flow-through step with Eshmuno<sup>®</sup> Q resin. The higher concentration feed reduces the solution volume needed to be processed through subsequent virus filtration and ultrafiltration steps. As a result, Eshmuno<sup>®</sup> CP-FT resin requires significantly less resin and buffer and is an ideal choice for the removal of aggregates within an intensified process.

Case study #2 with mAb02 found that using flow-through frontal chromatography with Eshmuno<sup>®</sup> CP-FT resin was more effective than CEX bind/elute chromatography and was able to reduce the level of mAb aggregates below the target of 1%. Even after optimizing the loading conditions (pH 6.0) and lowering the loading down from 80 g/L to 60 g/L, the level of aggregates could not be reduced below 1% using CEX bind/elute chromatography. The results indicate that flow-through chromatography with Eshmuno<sup>®</sup> CP-FT resin offers a special selectivity enabling the removal of aggregates from feeds with particularly difficult aggregates.

## **Flow-Through Virus Removal**

Clearance studies with Eshmuno<sup>®</sup> CP-FT resin were also performed to demonstrate the removal of both xenotropic murine leukemia virus (X-MuLV) and minute virus of mice (MVM) from a mAb05 feed under strong binding conditions in the flow-through mode. At a loading of 1,000 g/L, a cumulative log reduction value (LRV) of 3.4 was demonstrated for X-MuLV and 3.1 for MVM (Figure 5). The results indicate that using Eshmuno<sup>®</sup> CP-FT resin for the flow-through removal of aggregates also has the potential to positively contribute to the overall virus removal strategy for a downstream purification process.





#### Figure 5.


MAb05 feed with 10% aggregates was dialyzed into a buffer composed of 100 mM acetate at pH 5.0 and 5.0 mS/cm then spiked with virus and processed through a 1.0 mL (0.66 cm i.d., 3.0 cm bed height) column of Eshmuno<sup>®</sup> CP-FT resin. Virus removal was assessed throughout the run and LRVs are shown at increasing mass loading on Eshmuno<sup>®</sup> CP-FT resin. Collection points where no virus was detected are indicated with an arrow.

# **Proven Eshmuno® Technology**

Eshmuno<sup>®</sup> CP-FT resin is a member of our high performance Eshmuno<sup>®</sup> platform, which is a family of chromatography resins designed to meet the demands of highly productive downstream purification processes. Eshmuno<sup>®</sup> base beads (Figure 6) are composed of a hydrophilic polyvinyl ether polymer that enables high flow rates resulting in shorter processing times. Eshmuno<sup>®</sup> CP-FT resin can be easily packed into production-scale columns, either by simple flow packing or axial compression. The pressure-flow curves for 10 and 20 cm i.d. columns at 20 cm bed height are shown in Figure 7 demonstrating linear scalability.








# **Easy Sanitization**

Eshmuno<sup>®</sup> CP-FT resin is easily sanitized and has excellent stability under both alkaline and acidic conditions. Figure 8 demonstrates no significant differences in the separation of a three-protein mixture were observed after 100 clean-in-place (CIP) cycles (60-minutes exposure to 1.0 M sodium hydroxide per cycle).



#### Figure 8.

A solution composed of  $\beta$ -lactoglobulin (7.0 mg/mL), cytochrome C (4.5 mg/mL) and lysozyme (3.5 mg/mL) in 50 mM sodium acetate at pH 5.0 was loaded onto a 7.85 mL (1.0 cm i.d., 10 cm bed height) column of Eshmuno<sup>®</sup> CP-FT resin. The proteins were slowly eluted off the column using a linear gradient of 50 mM sodium acetate at pH 5.0 and was increased to 80% of 1.0 M sodium chloride at pH 5.0 over 10 CV. The chromatograms shows the separation of  $\beta$ -lactoglobulin, cytochrome C and lysozyme on Eshmuno<sup>®</sup> CP-FT resin after run 1 (blue), run 50 (magenta), and run 100 (green) in which each run includes a 60 minute clean-in-place treatment with 1.0 M NaOH.

## **Process Development Tools**

Eshmuno<sup>®</sup> CP-FT resin is available in pre-packed, ready-to-use columns. MiniChrom columns can be used for labscale process development with any standard chromatography system. RoboColumn<sup>®</sup> prepacked columns can be utilized for high-throughput process development in conjunction with a chromatography robot. These small-scale columns are the ideal tool for performing initial resin screening, scaling, and optimization studies.

#### Table 3.

Eshmuno<sup>®</sup> CP-FT Resin Characteristics

	Eshmuno <sup>®</sup> CP-FT Resin
Type of chromatography	Strong cation exchanger
Functional group	Sulfoisobutyl
Base material	Surface grafted rigid hydrophilic polyvinyl ether polymer
Mean particle size (d50)	50 µm
pK value	<1
pH stability	pH 2 to 14
Mechanical stability	8 bar
Linear flow rate	up to 400 cm/h (< 3.0 bar net pressure) 20 x 10 cm i.d. column, 10-12% compression equivalent to 1.11-1.14 compression factor, 150 mM NaCl as mobile phase
Storage conditions	20% EtOH + 150 mM NaCl solution, ambient temperature
Shipping solution	20% EtOH v/v+ 150 mM NaCl solution

## **Ordering information**

Description	Cotolog Number	
Description	Catalog Number	
Eshmuno® CP-FT resin, 10 mL	1.20093.0010	
Eshmuno® CP-FT resin, 100 mL	1.20093.0100	
Eshmuno® CP-FT resin, 500 mL	1.20093.0500	
Eshmuno® CP-FT resin, 5L	1.20093.5000	
MiniChrom prepacked column with Column Eshmuno <sup>®</sup> CP-FT resin, 1mL 8x20mm	1.25168.0001	
MiniChrom prepacked column with Column Eshmuno ® CP-FT resin, 5mL 8x100mm	1.25169.0001	
MiniChrom prepacked column with Column Eshmuno $^{\otimes}$ CP-FT resin, 0.2mL 5x10mm	1.25170.0001	
RoboColumn <sup>®</sup> prepacked column with Eshmuno <sup>®</sup> CP-FT resin, 0.2mL 8PC 5x10mm	1.25171.0001	
RoboColumn <sup>®</sup> prepacked column with Eshmuno <sup>®</sup> CP-FT resin, 0.6mL 8PC 5x30mm	1.25172.0001	
Buffer Preparation		
Phosphoric acid 75% EMPROVE® EXPERT	100250	
di-Potassium hydrogen phosphate anhydrous EMPROVE® EXPERT Ph Eur, BP, USP	137010	
Sodium chloride EMPROVE® EXPERT Ph Eur, BP, JP, USP	137017	
Sodium dihydrogen phosphate dihydrate EMPROVE <sup>®</sup> EXPERT Ph Eur, BP, USP, JPE	137018	
Sodium hydroxide pellets EMPROVE® EXPERT Ph Eur, BP, JP, NF	137020	
Sodium hydroxide solution 1 mol/L EMPROVE® EXPERT	137031	
Tris (hydroxymethyl)aminomethane (Trometamol) EMPROVE <sup>®</sup> ESSENTIAL Ph Eur,BP,JPC,USP	108386	
Tris (hydroxymethyl)aminomethane (Trometamol) high purity EMPROVE® EXPERT Ph Eur, BP, JPC, USP, ACS	108307	
Tris (hydroxymethyl)aminomethane hydrochloride EMPROVE® EXPERT	108219	
Hydrochloric acid 1 mol/L EMPROVE® EXPERT	110165	
Acetic acid 1 mol/L EMPROVE® EXPERT	137035	
Acetic acid 30% EMPROVE® EXPERT Ph Helv	137047	
Acetic acid (glacial) 100% EMPROVE® EXPERT Ph Eur,BP,JP,USP	137000	
Sodium acetate anhydrous EMPROVE® EXPERT USP	137046	
Sodium acetate trihydrate EMPROVE® EXPERT Ph Eur, BP, JP, USP	137012	
Column Cleaning & Storage		
Ethanol 20% EMPROVE® EXPERT	480910	
Ethanol 20 % (v/v) with 150 mMol/L sodium chloride solution EMPROVE® EXPERT	480940	
Guanidinium chloride EMPROVE® EXPERT	137037	
Sodium hydroxide solution 0,1 mol/L EMPROVE® EXPERT	137058	
Sodium hydroxide solution 0,5 mol/L EMPROVE® EXPERT	137060	
Ethanol absolute suitable for use as excipient EMPROVE® exp Ph Eur, BP, JP, USP	100986	
2-Propanol 70 % (v/v) EMPROVE® EXPERT USP	137040	
2-Propanol EMPROVE® ESSENTIAL Ph Eur, BP, JP, USP	100995	
Benzyl alcohol EMPROVE <sup>®</sup> EXPERT Ph Eur, BP, JP, NF, ACS	137043	

Merck KGaA Frankfurter Strasse 250 64293 Darmstadt, Germany For additional information, please visit www.merckmillipore.com.

To place an order or receive technical assistance, please visit www.merckmillipore.com/ contactPS



© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the vibrant M, Millipore, Eshmuno and Emprove are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.